

Silvia Bozzarelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6280548/publications.pdf>

Version: 2024-02-01

20
papers

472
citations

932766

10
h-index

839053

18
g-index

20
all docs

20
docs citations

20
times ranked

1086
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 204.	1.1	3
2	Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. <i>Cancers</i> , 2022, 14, 1168.	1.7	0
3	The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 425-435.	1.9	3
4	Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 5665.	1.7	5
5	Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. <i>British Journal of Radiology</i> , 2020, 93, 20190627.	1.0	11
6	Preoperative or Perioperative Docetaxel, Oxaliplatin, and Capecitabine (GASTRODOC Regimen) in Patients with Locally-Advanced Resectable Gastric Cancer: A Randomized Phase-II Trial. <i>Cancers</i> , 2020, 12, 2790.	1.7	15
7	Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. <i>Clinical Colorectal Cancer</i> , 2019, 18, 125-132.e2.	1.0	35
8	Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND). <i>Future Oncology</i> , 2019, 15, 4009-4017.	1.1	8
9	Targeted agents for second-line treatment of advanced hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 788-803.	0.8	8
10	Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e489-e498.	1.0	16
11	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , 2017, 22, 1463-1469.	1.9	27
12	Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. <i>Gastric Cancer</i> , 2017, 20, 428-437.	2.7	5
13	KRAS mutation in lung metastases from colorectal cancer: prognostic implications. <i>Cancer Medicine</i> , 2016, 5, 256-264.	1.3	29
14	FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study. <i>Clinical Colorectal Cancer</i> , 2015, 14, 162-169.	1.0	11
15	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. <i>Radiotherapy and Oncology</i> , 2015, 117, 315-321.	0.3	28
16	Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1179-1187.	1.2	34
17	A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2013, 18, 379-380.	1.9	34
18	Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 57, 101-107.	1.8	191

#	ARTICLE	IF	CITATIONS
19	Case Report of Acute Aortic Dissection during Treatment with Capecitabine for a Late Recurrence of Breast Cancer. <i>Chemotherapy</i> , 2010, 56, 203-207.	0.8	9
20	Tumour burden score and immune-related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors. <i>Liver Cancer International</i> , 0, , .	0.2	0